- Home
- CEE vs GNLX Comparison
CEE vs GNLX Comparison
Compare CEE & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.96
Company Overview
Basic Information| Metric | CEE | GNLX |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.3M | 113.6M |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CEE | GNLX |
|---|---|---|
| Price | $20.90 | $2.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 21.4K | ★ 161.3K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.25 | $2.29 |
| 52 Week High | $21.98 | $8.54 |
Technical Indicators
Market Signals| Indicator | CEE | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 54.44 |
| Support Level | $16.97 | $2.33 |
| Resistance Level | $21.92 | $3.25 |
| Average True Range (ATR) | 0.74 | 0.17 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 46.98 | 46.08 |
Price Performance
Historical Comparison CEE
GNLX
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.